CRAC

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, Conference, Pneumonia, CRAC, Disease, Incidence, GFR, AKI, Patient, Physiology, COVID-19, Renal artery, Biomarker, Hemofiltration, T helper 17 cell, Mortality, Indiana University, Cell biology, Glomerular filtration rate, Respiratory failure, Doctor of Philosophy, Acute kidney injury, Ischemia, Kidney, Poster, Stage 2, Blood, Animal, Hospice and palliative medicine, Pharmaceutical industry

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points: 
  • In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
  • We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
  • The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
  • These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

Global Hyperscale Data Center Market Outlook & Forecasts 2023-2028: Growing Procurement of Artificial Intelligence, Big Data and IoT Solutions Presents Burgeoning Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Technology, Networks, Data Management, Artificial intelligence, Investment, T-Mobile, Growth, UPS, Automation, Social media, MIA, Renewable energy, National university, Carrier, Big data, Cloud computing, Machine learning, Microsoft, AWS, EIA, YTL, PPA, CRAC, HVO, Internet, Thor Equities, AI, Internet of things, Equinix, Deep learning

The "Global Hyperscale Data Center Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hyperscale Data Center Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • Globally, major hyperscale data center market companies are prioritizing using renewable energy as their primary power source.
  • Most operators in the global hyperscale data center market primarily employ free cooling solutions, and there is also a growing trend in data centers toward adopting waterless cooling systems that use free cooling chillers and indoor CRAC units.
  • In response to a growing trend, companies that provide data center infrastructure services are increasingly adopting environmentally friendly and efficient solutions.

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Retrieved on: 
Tuesday, February 13, 2024
Oxygen, International, Chronic kidney disease, Incidence, FDA, Food, Dialysis, Glomerular filtration rate, Pneumonia, Hemofiltration, IRI, Risk, Conference, IMV, Angiopoietin, CRAC, Survivor, COVID-19, Classification, Death, Acute kidney injury, EGFR, AHRF, Patient, Biomarker, AKI, Survival, Disease, Kidney disease, Medicine, GFR, Endothelium, IND, Mortality, Pharmaceutical industry

LA JOLLA, Calif., Feb. 13, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, Auxora™, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.

Key Points: 
  • CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.
  • "Through KOURAGE, we aim to determine how Auxora can benefit patients with severe AKI and potentially reduce the high mortality rate associated with this disease."
  • AKI is classified as stages 1, 2 and 3 depending on the degree of kidney injury.
  • A single dose of Auxora after IRI increased GFR by 61% and decreased mononuclear (inflammatory) cell infiltration by 30%.

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Wednesday, February 7, 2024
CRAC, Webcast, Conference

LA JOLLA, Calif., Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:40am – 11:10am ET.

Key Points: 
  • LA JOLLA, Calif., Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:40am – 11:10am ET.
  • A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/ .
  • A replay of the webcast will be archived on the Company's website for 90 days.

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Retrieved on: 
Thursday, November 2, 2023
Acute lymphoblastic leukemia, CRAC, T16, Asparaginase, LA, Society, Severity, ASH, Pancreatitis, TPN, AAP, St. Jude Children's Research Hospital, Patient, ALL, Parenteral nutrition, ICU, Pharmaceutical industry

LA JOLLA, Calif., Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • The presentation includes results from the first cohort consisting of nine patients from the CRSPA study.
  • ONCASPAR™ and RYLAYZE™), a nearly identical ALL treatment protocol as used in the CRSPA study.
  • Additionally, no CRSPA patients required total parenteral nutrition (TPN), compared to 68.8% in the historical matched control group.
  • Presentation Title: Zegocractin to Reduce the Severity of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: Results of the Phase 1 Portion of the CRSPA Study

PROCOMER promotes the Costa Rican aerospace industry at the most important international trade fair of the sector.

Retrieved on: 
Friday, October 27, 2023
Lisk, CRAC, Aircraft, Federal Aviation Administration, Banco Latinoamericano de Comercio Exterior, Export Development Canada, Maintenance, Multimedia, Electronics, Joby Aviation, Costa Ricans, NBAA, FAA, SAN, Airline

The Costa Rican delegation, led by PROCOMER, is composed of the companies Avionyx, Aerocalidad, Camtronics, Olympic Precision Machining, BOF Construction Advisor, GJ Cargo, Grupo Mitah Escazú PREINSA, TicoElectronics (both part of G.W.

Key Points: 
  • The Costa Rican delegation, led by PROCOMER, is composed of the companies Avionyx, Aerocalidad, Camtronics, Olympic Precision Machining, BOF Construction Advisor, GJ Cargo, Grupo Mitah Escazú PREINSA, TicoElectronics (both part of G.W.
  • Lisk), which offer machining services, specialized software, electrical, electronics, logistics, real estate, as well as maintenance and repair of aerospace equipment.
  • Mario Sáenz, PROCOMER's Export Development Manager, highlighted how important it is for Costa Rican companies to participate in international events and promote the human talent that Costa Rica has to offer in a sector as specialized as aerospace.
  • Additionally, Esteban Carrillo, Executive Director of Costa Rica Aerospace Cluster (CRAC), a consortium that brings together more than 30 aerospace companies in Costa Rica, emphasized that "the participation of Costa Rica Aerospace Cluster in NBAA 2023 marks an important milestone in the consolidation of the aerospace market.

CalciMedica Announces Upcoming Presentations and Events in September

Retrieved on: 
Wednesday, September 6, 2023
IR, Nutrition, Emergency medicine, Ohio State University College of Dentistry, CRAC, Henry Ford Health, Associate, Emergency, Ohio State University College of Medicine, Michigan State University, Conference, Pharmaceutical industry, Gastroenterology

LA JOLLA, Calif., Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 1:30 p.m. – 2:00 p.m. ET/ 10:30 a.m. – 11 a.m. PT.

Key Points: 
  • LA JOLLA, Calif., Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 1:30 p.m. – 2:00 p.m. ET/ 10:30 a.m. – 11 a.m. PT.
  • The Company will also be hosting a virtual Acute Pancreatitis Clinical Experts Event on Thursday, September 21, 2023, from 10:30 a.m. – 12 p.m. ET/ 7:30 a.m. – 9 a.m. PT featuring Joseph Miller, M.D., Clinical Associate Professor of Emergency Medicine at Henry Ford Health and Michigan State University and Associate Director of Emergency Care Research at Henry Ford Health, and Georgios Papachristou, M.D., Ph.D., Professor of Medicine, Floyd Beman Endowed Chair in Gastroenterology and division director for Gastroenterology, Hepatology and Nutrition at The Ohio State University College of Medicine.
  • Live webcasts of both events, as well as registration for the clinical experts event, can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/ .
  • A replay of the Acute Pancreatitis Clinical Experts Event will be available for one year following the completion of the event, and a replay of the conference presentation will be available for 90 days.

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Retrieved on: 
Thursday, August 31, 2023
Ohio State University College of Dentistry, Michigan State University, CRAC, Ohio State University College of Medicine, IR, Emergency medicine, Henry Ford Health, Nutrition, Emergency, Pharmaceutical industry, Gastroenterology, Medicine

LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 a.m. – 12 p.m. ET/ 7:30 a.m. – 9 a.m. PT.

Key Points: 
  • LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 a.m. – 12 p.m. ET/ 7:30 a.m. – 9 a.m. PT.
  • CalciMedica management will be joined by clinical experts Joseph Miller, M.D., clinical associate professor of Emergency Medicine at Henry Ford Health and Michigan State University and associate director of Emergency Care Research at Henry Ford Health, and Georgios Papachristou, M.D., Ph.D., professor of Medicine, Floyd Beman Endowed Chair in Gastroenterology and division director for Gastroenterology, Hepatology and Nutrition at The Ohio State University College of Medicine in discussing the Company's lead clinical compound, Auxora™, and its potential implications in acute pancreatitis.
  • Registration for the event will be available in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/ beginning at 7:30 a.m.
  • ET on Wednesday, September 6.

CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Retrieved on: 
Thursday, August 10, 2023
University, RAP, Senior, University of Szeged, CRAC, CP, Drug, AP, Jude the Apostle, AKI, Acute kidney injury, Journal, Patient, Security (finance), Acute pancreatitis, Systemic inflammatory response syndrome, IND, SIRS, Pharmaceutical industry, Management, Nursing

LA JOLLA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • LA JOLLA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2023.
  • “Following the completion of our reverse merger in March 2023, CalciMedica has taken critical steps to accelerate clinical activities with our lead compound, Auxora,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
  • Patient enrollment from additional sites is expected to begin in the fourth quarter of 2023.
  • The majority of costs stemming from the reverse merger have been expensed including the payment of accrued transaction expenses in the second quarter.

Saddleback Communications Upgrades its Environmental and Power Infrastructure for the Future

Retrieved on: 
Thursday, August 10, 2023
Maintenance, Failure, Salt River Pima–Maricopa Indian Community, CRAC, Human, AC, Generator, SRPMIC, Community, Wildfire, Growth, Safety, Saddleback College, Saddleback

SCOTTSDALE, Ariz., Aug. 10, 2023 /PRNewswire/ -- Following recent announcements of new growth and expansion within the Salt River Pima-Maricopa Indian Community, Saddleback Communications shares it is investing more than $2 million to upgrade and modernize its power and environmental infrastructure – including power, battery and generator systems, as well as new cooling and AC – to support the Community's existing and new development.

Key Points: 
  • Saddleback's updates will balance the power load and eliminate any single points of failure while broadening the scope of monitoring and alerting software.
  • The communications company has provided highly reliable fiber-based internet, voice and cloud communications service to the Salt River Pima-Maricopa Indian Community (SRPMIC) for the past 25 years.
  • "The investment underscores our commitment to the businesses and residents within the Community," says Saddleback Communications President and General Manager Bill Bryant.
  • These upgrades and improvements build upon Saddleback's 25-year history of exceptionally reliable communications infrastructure to serve the SRPMIC community for the next 25 years of rapid growth.